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Most potent protein kinase inhibitors act by
competing with ATP to block the phosphotransfer-
ase activity of their targets. However, emerging evi-
dence demonstrates that ATP-competitive inhibitors
can affect kinase interactions and functions in ways
beyond blocking catalytic activity. Here, we show
that stabilizing alternative ATP-binding site confor-
mations of the mitogen-activated protein kinases
(MAPKs) p38a and Erk2 with ATP-competitive inhibi-
tors differentially, and in some cases divergently,
modulates the abilities of these kinases to interact
with upstream activators and deactivating phospha-
tases. Conformation-selective ligands are also able
to modulate Erk2’s ability to allosterically activate
the MAPK phosphatase DUSP6, highlighting how
ATP-competitive ligands can control noncatalytic
kinase functions. Overall, these studies underscore
the relationshipbetween theATP-bindingand regula-
tory sites of MAPKs and provide insight into how
ATP-competitive ligands can be designed to confer
graded control over protein kinase function.
INTRODUCTION
Protein kinases are one of the largest protein families encoded
by the human genome and major constituents of most intracel-
lular signaling cascades (Manning et al., 2002a, 2002b). These
signaling enzymes play important roles in countless cellular
pathways, and the proper regulation of their activity is essential
for normal cellular behavior. Aberrant kinase function is linked
to numerous diseases, and a number of kinases are promising
targets for the development of small-molecule-based therapies
(Cohen and Alessi, 2013). Currently, a majority of potent and
selective kinase inhibitors block phosphotransferase activity by
competing with ATP (Zhang et al., 2009). Althoughmany of these
inhibitors are able to interact with the ATP-binding clefts of
kinases in an active conformation, a subset of inhibitors is
conformation selective, in that they only bind to their targets if
conserved catalytic residues have been displaced from a cata-628 Chemistry & Biology 21, 628–635, May 22, 2014 ª2014 Elsevierlytically competent conformation. Many kinases can be inhibited
by ATP-competitive ligands with different binding modes, due to
the conformational plasticity of their active sites.
Over the last five years it has become apparent that ATP-
competitive inhibitors can affect kinases in ways beyond
blocking their phosphotransferase activity. For example, the
activation loop of the serine/threonine (S/T) kinase Akt becomes
hyperphosphorylated when its ATP-binding site is occupied by
small-molecule inhibitors (Chan et al., 2011; Okuzumi et al.,
2009). Additionally, it has been shown that many inhibitors of
the S/T kinase Raf promote trans-dimer autoactivation (Hatzi-
vassiliou et al., 2010; Poulikakos et al., 2010), which may
contribute to undesired drug responses in the clinic (Cichowski
and Ja¨nne, 2010). Importantly, there is emerging evidence that
it is possible to produce different, in some cases divergent,
effects by varying the active site interactions made by ATP-
competitive inhibitors. For example, conformation-selective in-
hibitors are able to either activate or inactivate the RNase domain
of the bifunctional kinase/RNase Ire1a, depending on whether
they stabilize an active or inactive ATP-binding site conformation
(Wang et al., 2012). We have also demonstrated that different
classes of ATP-competitive inhibitors can divergently modulate
the regulatory domain accessibility of Src-family kinases (Krish-
namurty et al., 2013).
Whereas the above examples demonstrate that it is possible
for different classes of ATP-competitive inhibitors to differentially
modulate interactions and functions outside of kinase active
sites, the overall generality of these phenomena to the rest of
the kinome is unclear. We were particularly interested in whether
these observations can be extended to the mitogen-activated
protein kinase (MAPK) family because these kinases are central
components of numerous signaling pathways, and a number of
noncatalytic MAPK functions have been reported (Rodrı´guez
and Crespo, 2011). Because MAPKs have no regulatory do-
mains and devote much of their exposed surface area to inter-
acting with other proteins, there is the intriguing possibility that
their noncatalytic functions can be modulated by ligands that
stabilize different ATP-binding site conformations.
Here, we report that conformation-selective ATP-competitive
inhibitors are able to differentially modulate the regulatory inter-
actions of MAPKs (Figure 1). We show that the specific con-
formations stabilized by these ligands dictate the behavior
of MAPKs toward their activators (MAPK kinases) and inactiva-
tors (dual-specificity phosphatases). We also demonstrate thatLtd All rights reserved
Figure 1. Modulation of Kinase Regulation and Function by Stabiliz-
ing Alternative Active Site Conformations
Protein kinases, such as Erk2, are regulated by multiple phosphorylation and
dephosphorylation events. Furthermore, many kinases are known to have a
number of noncatalytic functions, such as scaffolding and allosteric activation.
Conformation-selective inhibitors can potentially be used to modulate the
regulatory and noncatalytic interactions of protein kinases.
Figure 2. MAPK Active Site Conformational Plasticity
(A) Superimposed structures of Erk2 in the active DFG-in (blue; DFG motif in
teal) (Protein Data Bank [PDB] ID code 1PME) and inactive DFG-out (yellow;
DFG motif in magenta) (PDB ID code 4I5H) conformations. The DFG-motif
phenylalanine residues for both structures are shown in stick form, and the
distance between their a carbons is 9.6 A˚. Portions of the p-loops are hidden
for clarity.
(B) Inhibitors used in this report that stabilize the active DFG-in (SB203580) and
inactive DFG-out (1 and 2) conformations. Crystal structures of these ligands
stabilizing specific kinase conformations can be found in the Protein Data
Bank under ID codes 1A9U (SB203580), 2BAJ (1), and 4I5H (2).
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independent of phosphotransferase activity. The examples pre-
sented herein provide compelling evidence that ATP-binding site
ligands can differentially modulate a diverse number of protein
kinase interactions.
RESULTS AND DISCUSSION
Conformation-Selective Inhibitors Prevent the In Vitro
Activation of Erk2
Two recurrent ATP-binding site conformations are characterized
by the orientations of protein kinase activation loops, specifically
the conserved Asp-Phe-Gly (DFG) motif, which is near the base
of this flexible structural element (Figure 2A). In the active confor-
mation (DFG-in), the DFGmotif and all of the catalytic residues in
the ATP-binding site are aligned for catalysis. In contrast, many
kinases can also adopt an inactive conformation (DFG-out), in
which the DFGmotif is translocated from an active conformation
to accommodate a conformation-selective inhibitor. Regardless
of the conformation stabilized, both modes of ATP-competitive
inhibition lead to a loss of phosphotransferase activity. However,
Sullivan et al. reported that when the MAPK p38a is stabilized in
the DFG-out conformation with ligands, such as pyrazolourea (1)
(Figure 2B), its activation loop cannot be phosphorylated by its
upstream MAPK kinase (MEK) (Sullivan et al., 2005). Because
activation loop phosphorylation is necessary for efficient cata-
lytic activity, these inhibitors prevent the activation of p38a.
However, when stabilized in the active DFG-in conformation by
the p38a inhibitor SB203580, the phosphorylation (and subse-
quent activation) of p38a proceeds uninhibited. Still unknown,
however, is whether this effect is specific to p38a or more
broadly applicable to other MAPKs. We were particularly inter-
ested in Erk2 due to the substantial number of noncatalytic func-
tions that are mediated by the activation-loop-phosphorylated
form of this kinase (Rodrı´guez and Crespo, 2011). If Erk2 must
be activated to interact with certain proteins, then inhibitors
that block its phosphorylation will also hinder these noncatalytic
functions. However, wild-type Erk2 (Erk2WT) is very weakly in-Chemistry & Biology 21,hibited by SB203580 and ligands, like 2, that stabilize the
DFG-out inactive conformation (Figures 3A, 3B, and 3E). To
overcome this limitation, we utilized two drug-sensitive Erk2
mutants (ERK2DS1: Q103T/C164L; ERK2DS2: Q103A/C164L)
that are highly sensitive to inhibitors 2 and SB203580 (Hari
et al., 2013).
First, the effects of ligands 2 and SB203580 on the activation
of Erk2 by its upstream kinase, MEK2, were probed using an
in vitro activation assay (Figures 3C–3E). Varying concentrations
of each inhibitor (2 or SB203580) were incubated with a fixed
concentration of Erk2DS1 and MEK2 in the presence of ATP.
The amount of bis-phosphorylated Erk2 produced in the reaction
was then quantified by ELISA. These data indicate that ligand 2
potently inhibits the dual phosphorylation of Erk2’s activation
loop (Figures 3D and 3E). In contrast, SB203580 had only a min-
imal effect on the ability of MEK2 to activate Erk2. These results
closely resemble the behavior observed for MEK6-mediated
activation of p38a first reported by Sullivan et al. (2005) and
confirmed presently (Table S1A available online). To rule out
the possibility that ligands 2 and SB203580 directly inhibit
MEK2, which would also lead to decreased levels of phospho-
Erk2, the assays were repeated with Erk2WT, which is insensitive
to both compounds (Figure 3B; Table S1B). As expected, neither
2 nor SB203580 led to a significant decrease in the amount of
activation-loop-phosphorylated Erk2WT (Figure 3D; Table S1B),
strongly suggesting that stabilization of the DFG-out conforma-
tion of Erk2 is the primary factor behind activation inhibition.
Full activation of MAPKs requires both residues on the TxY
motif on the activation loop to be phosphorylated. Therefore,
we determined whether 2 inhibits the phosphorylation of628–635, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 629
Figure 3. The Effects of Conformation-Selective Ligands on MAPK Activation by Upstream MEKs
(A) Schematic of the assay used to determine Erk2 inhibitory constants (Kis).
(B) Inhibition of Erk2WT and Erk2DS1 by 2 and SB203580. Data for 2 were reported previously (Hari et al., 2013).
(C) Schematic of the assay used to determine activation loop phosphorylation inhibition of Erk2.
(D) Inhibition of Erk2WT and Erk2DS1 activation loop phosphorylation by 2 and SB203580. The amount of bis-phosphorylated Erk2 produced at each inhibitor
concentration was determined by ELISA.
(E) Enzymatic inhibition (Ki) and EC50 values for Erk2
WT and Erk2DS1 against ligands 2 and SB203580. Ki values were reported previously (Hari et al., 2013).
aPartial
inhibition (20%–30%) at saturating inhibitor concentrations.
Error bars represent SEM for three replicate measurements. See also Figure S1 and Tables S1A and S1B.
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do so, Erk2DS1 was activated byMEK2 in the presence of DMSO,
ligand 2, or SB203580, and the phosphorylated isoforms of the
kinase were separated by PhosTag-acrylamide PAGE (Kinoshita
et al., 2004). This analysis revealed that inhibitor 2 completely
prevents the formation of any bis-phosphorylated Erk2 but per-
mits somemonophosphorylated product formation (Figure S1A).
In contrast, comparable levels of bis-phosphorylation were
observed for apo Erk2DS1 and SB203580-bound Erk2DS1. Inter-
estingly, we found that stabilizing p38a in the inactive DFG-out
conformation with ATP-competitive inhibitor 1 completely pre-
vents activation loop phosphorylation by MEK6 (Figure S1B).
This result builds on the data reported by Sullivan et al. (2005)
through the analysis of individual phosphoisoforms of p38a to
show that neither site on the TxY motif is appreciably phosphor-
ylated in the presence of inhibitor 1. Therefore, there appear to
be some subtle differences in how conformation-selective inhib-
itors influence the ability of MEKs to interact with and activate
p38a and Erk2.
Conformation-Selective Inhibitors Prevent Erk2
Activation in Cells
Having demonstrated the ability of ligand 2 to potently block
Erk2DS1 activation in vitro, we were interested in whether this
effect could be observed in a cellular environment. Therefore,630 Chemistry & Biology 21, 628–635, May 22, 2014 ª2014 ElsevierGFP-tagged Erk2 (WT or DS1) was transiently transfected
into HEK293 cells, which were then incubated with either 2 or
SB203580. The cells were then briefly stimulated with epidermal
growth factor (EGF) to activate the Erk pathway (Robinson et al.,
2002). Immunoblot analysis showed that addition of 2 prevented
Erk2DS1 activation upon stimulation, whereas SB203580 had
no effect (Figure 4). Consistent with the in vitro insensitivity of
Erk2WT to 2 and SB203580, the cellular activation of this kinase
was not affected by the presence of either inhibitor.
Characterization of an Alternative Inactive ATP-Binding
Site Conformation of Erk2
Although upstream MEKs are unable to activate p38a and Erk2
that are bound to ligands that stabilize the DFG-out inactive
conformation, it is unclear whether this effect is due to the sub-
strate MAPK being in the DFG-out conformation or whether this
is due to these kinases’ inability to access their active form.
Therefore, we conducted a screen in order to identify inhibitors
of Erk2 that stabilize the other most frequently observed inactive
ATP-binding site conformation in kinases, the Src/Cdk-like or
helix aC-out inactive conformation (Jura et al., 2011). In this inac-
tive form, the DFG motif in the activation loop adopts a nearly
active conformation, but movement of helix aC in the N-terminal
lobe disrupts a key salt bridge between the catalytic lysine and a
conserved glutamic acid (Figure 5B). Although no ligands thatLtd All rights reserved
Figure 4. Cellular Inhibition of Erk2 Activation
GFP-tagged Erk2WT or Erk2DS1 was transiently transfected into HEK293 cells.
After serum starvation, the cells were incubated with DMSO (lanes 1 and 2),
ligand 2 (lanes 3–6 [1,000, 500, 300, and 100 nM]), or SB203580 (lane 7
[1,000 nM]). EGF was then added (lanes 2–7), followed by cell lysis, SDS-
PAGE, and immunoblotting (IB).
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we felt that our drug-sensitive Erk2 mutants may be susceptible
to inhibition by a series of previously characterized conforma-
tion-selective Src inhibitors (Krishnamurty et al., 2013). Indeed,
inhibitor 3 (Figure 5A), which contains a bulky benzyl group
that is predicted to be sterically incompatible with the active
conformation of helix aC, inhibits Erk2DS2 (Ki 133 nM).
To test whether 3 stabilizes the helix aC-out conformation of
Erk2 as predicted, the crystal structure of 3-bound Erk2DS2
was determined (Figure 5B; Table S2). This structure is very
similar to that of Erk2 bound to the inhibitor SB203580, with
an overall root-mean-square deviation of 0.854 A˚. Equally alike
are the positions of their activation loops; both are stabilized in
the DFG-in conformation, which starkly contrasts with that of
2-bound Erk2DS2 (Figure 5C). As expected, the benzyl group of
3 is directed toward helix aC, disrupting the salt bridge between
Glu-69 and the catalytic lysine (Lys-52). Somewhat surprisingly,
helix aC does not rotate and move away from the active site to
accommodate the benzyl moiety of ligand 3; instead, Glu-69
on helix aCsimply assumes amore compact rotamer (Figure 5D).
Therefore, although the active site movements induced by ligand
3 still disrupt the salt bridge betweenGlu-69 and Lys-52, which is
the salient feature of the helix aC-out inactive conformation, they
do so without changing the position of helix aC. Given that a
close analog of 3 causes a rotation and translocation of Src’s
helix aC (Krishnamurty et al., 2013), it is unclear why 3 does
not induce a similar change in Erk2 (Figure S2A). Even the inac-
tive form of the S/T kinase Cdk2, which is 50% similar in
sequence to Erk2, presents the more canonical helix aC-out
conformation (Schulze-Gahmen et al., 1996). However, superim-
posing cyclin-bound active Cdk2 with 3-bound Erk2 suggests
that Erk2’s C-terminal extension (L16), which is not present in
Src or CDK2, behaves like cyclin to keep helix aC packed in
the active site (Figure S2B). However, more work is required to
validate this hypothesis.
To determine the effect of 3 on MEK2-mediated phosphoryla-
tion of Erk2DS2, ligand 3was titrated into a fixed concentration of
Erk2DS2, after which ATP and MEK2 were added. The amount of
bis-phosphorylated Erk2 generated was quantified by ELISA.
Although 3 directly inhibits MEK2, this inhibitor does not appear
to prevent activation loop phosphorylation through its interaction
with Erk2DS2 (Table S1B). Therefore, the inhibition of activationChemistry & Biology 21,loop phosphorylation that is observed in the presence of 2 is
most likely due to stabilization of Erk2 in the DFG-out inactive
conformation.
Divergent Modulation of MAPK Dephosphorylation with
Conformation-Selective Inhibitors
Because conformation-selective inhibitors can prevent MAPK
activation loop phosphorylation, we predicted that their cognate
dephosphorylation would also be sensitive to these ligands (Fig-
ure 6A). MAPKs are selectively dephosphorylated at both resi-
dues on their TxY motifs in the activation loop by dual-specificity
phosphatases (DUSPs) (Sun et al., 1993). The specificities
of DUSPs vary, but DUSP6 is reported to target Erk MAPKs
(Muda et al., 1996). For this reason, DUSP6 was used to de-
phosphorylate activation-loop-phosphorylated Erk2DS2 in the
presence of inhibitors 2, 3, or SB203580, and this reaction was
monitored by following the decrease of activated Erk2 by ELISA.
Similar to its ability to prevent the phosphorylation of Erk2, 2
limits the ability of DUSP6 to dephosphorylate the TxY motif
(Figure 6B; Table S3). Interestingly, both 3 and SB203580
enhanced the phosphatase activity of DUSP6, resulting in
increased dephosphorylation of phospho-Erk2DS2 relative to
the apo enzyme. To exclude the possibility of the direct enzy-
matic activation or inhibition of DUSP6, the experiment was
repeated with phospho-Erk2WT; as expected, none of the inhib-
itors affected the ability of DUSP6 to dephosphorylate this
kinase. Therefore, 2, 3, and SB203580 affect DUSP6 activity
by modulating the conformation of its substrate, phospho-Erk2.
To see whether this effect applied to other MAPKs, the same
experiment was performed with p38a and its specific phospha-
tase DUSP10 (Figure 6C) (Tanoue et al., 1999). Similar to what
was observed for Erk2, SB203580 and 1 enhanced and reduced,
respectively, the dephosphorylation of phospho-p38a. Hence,
the combined results from p38a and Erk2 reveal divergent regu-
lation of signal transduction through the use of inhibitors that
stabilize distinct ATP-binding site conformations. Although the
exact mechanism of this regulation is not yet fully established,
it is logical that the10 A˚ translocation undergone by the activa-
tion loop (Figure 2A), which is characteristic of the DFG-out inac-
tive conformation, would influence enzymes (such as MEKs and
DUSPs) that closely interact with this motif. Less clear, however,
is how ligands such as 3 and SB203580, which stabilize the acti-
vation loop in the DFG-in conformation, enhance the ability of
MAPKs to be acted upon by these enzymes.
Conformation-Selective Inhibitors Modulate Erk2’s
Ability to Allosterically Activate a Phosphatase
Having demonstrated that conformation-selective inhibitors can
modulate the posttranslational regulation of Erk2, we wondered
whether these same ligands were also able to influence the non-
catalytic roles of this kinase. One of these interesting noncata-
lytic phenomena also involves DUSP6. Camps et al. reported
that the catalytic activity of this phosphatase for exogenous
substrates is increased by noncovalent interaction with Erk2
(Figure 7A) (Camps et al., 1998). To test the effects of our confor-
mation-selective inhibitors on DUSP6 activation, the abilities of
the drug-sensitive Erk2 mutants to activate DUSP6 were first
determined by following the turnover of 4-methylumbelliferyl
phosphate (4-MUP), which yields a fluorescent product upon628–635, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 631
Figure 5. Erk2DS2 Stabilized in a Modified Helix aC-Out Conformation
(A) Structure of ligand 3.
(B) Overall topology of 3-bound Erk2DS2. Helix aC is shown in yellow, the activation loop is in magenta, and 3 is in green.
(C) Superimposed structures of 3-bound Erk2DS2 (gray and yellow with magenta activation loop), SB203580-bound pentamutant Erk2 (cyan) (PDB ID code
1PME), and 2-bound Erk2DS2 (blue) (PDB ID code 4I5H). The DFG-motif phenylalanine residues for all three structures are represented in stick form. The distances
from the a carbon of the phenylalanine residue in 2-bound Erk2DS2 from those of 3- and SB203580-bound Erk2 are 11.1 and 9.6 A˚, respectively.
(D) Superimposed structures of 3-bound Erk2DS2 (gray and yellow), SB203580-bound pentamutant Erk2 (cyan) (PDB ID code 1PME), and 2-bound Erk2DS2 (blue)
(PDB ID code 4I5H). Glu-69 and Lys-52 for all three structures are represented in stick form. The distances between these residues for 3-, 2-, and SB203580-
bound Erk2 are 7.6, 2.7, and 2.7 A˚, respectively.
See also Figure S2 and Table S2.
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Erk2 mutants activate DUSP6 to the same extent as Erk2WT
(Figure S3A).
Next, how 2, 3, and SB203580 influence the ability of Erk2 to
activate DUSP6 was tested by incubating these ligands with
DUSP6, 4-MUP, and Erk2DS1 or Erk2DS2 (Figure 7B; Figure S3B).
Interestingly, 2 almost completely suppressed the activation of
DUSP6 by the drug-sensitive Erk2 mutants. In contrast, neither
3 nor SB203580 demonstrated a comparable inhibitory effect,
with both inhibitor-bound Erk2 complexes showing similar acti-
vation as apo Erk2. Again, none of these ligands affected the
ability of Erk2WT to activate DUSP6. In summary, these results
suggest that Erk2 is interacting with DUSP6 on or close to the
activation loop, and stabilizing this kinase in theDFG-out inactive
conformation is sufficient to disrupt this interaction.
To gain mechanistic insight into this effect, apo Erk2DS1 or the
2-Erk2DS1 complex was titrated into DUSP6, and the consump-
tion of 4-MUP was measured (Figure 7C). Interestingly, the con-
centrations of apo Erk2DS1 and 2-Erk2DS1 necessary to achieve
50% maximal activation of DUSP6 are similar. Therefore, it ap-
pears that 2 does not notably disrupt the interaction of Erk2
with DUSP6. Instead, Erk2’s interaction with 2 decreases the
ability of bound Erk2 to activate phosphatase activity. Further-
more, 2 does not appear to affect the ability of DUSP6 to act
upon its substrates, as the DUSP6-Erk2DS1 and DUSP6-
Erk2DS1-2 complexes have similar Michaelis constants (Km)
for 4-MUP (Figure S3C). A model by Zhou et al. based on
hydrogen-deuterium exchange experiments proposes that the
substrate-binding domain of Erk2 is critical for DUSP6 activation
(Zhou et al., 2006). The positions of the residues that form the
substrate-binding domain are largely unperturbed when Erk2 is
in the DFG-out conformation (Figure S3D), which explains why
ligand 2 does not change the affinity of Erk2 for DUSP6. Our re-
sults suggest that an interaction between the activation loop of
Erk2 and DUSP6 is necessary for allosteric phosphatase activa-632 Chemistry & Biology 21, 628–635, May 22, 2014 ª2014 Elseviertion. The ability to control the conformation of Erk2’s activation
loop with conformation-selective ligands presents the oppor-
tunity to modulate a number of noncatalytic functions of this
kinase.
SIGNIFICANCE
The conventional mode of action of protein kinase inhibitors
is to block phosphotransferase activity, but a growing body
of evidence strongly indicates that these inhibitors can also
affect regions distal to the active site. It is worthwhile to
consider that these changes may lead to effects of thera-
peutic relevance.
We have demonstrated that conformation-selective inhib-
itors have differential effects on the regulatory interactions
of MAPKs. Activation, deactivation, and noncatalytic allo-
steric enzyme activation can be modulated by the confor-
mations stabilized by these inhibitors. Because MAPKs are
implicated in a number of noncatalytic functions in the cell,
such as scaffolding and transcriptional regulation, it may
be possible to control diverse cellular processes through
the ATP-binding sites of MAPKs. Specifically, perturbation
of the activation loop using a specific class of ATP-compet-
itive inhibitors consistently alters MAPK posttranslational
modification and noncatalytic function. Although the results
in this study highlight the importance of the activation
loop in modulating these effects, it remains to be seen
how general this observation is in other kinase families.
The increasing availability of conformation-selective ligands
will facilitate these studies.
Therefore, although the generality of the phenomena
reported here is still unknown, given the growing number
of identified noncatalytic protein kinase functions, it is highly
possible that targeting the active site to control functions
that do not rely on catalytic activity will become a viableLtd All rights reserved
Figure 6. The Effects of Conformation-Selective Inhibitors on MAPK Dephosphorylation
(A) Schematic for MAPK dephosphorylation.
(B) Effect of ligands 2, 3, and SB203580 on DUSP6-mediated dephosphorylation of phospho-Erk2WT and phospho-Erk2DS2.
(C) Effect of ligand 1 or SB203580 on DUSP10-mediated phospho-p38a dephosphorylation.
Error bars represent SEM for three replicate measurements. See also Table S3.
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oped for this study could easily be adapted to high-
throughput formats, and we have demonstrated that
cell-based experiments are also possible. Thus, as more
noncatalytic functions are identified, it is both important
and experimentally feasible to develop biochemical assays
that can be incorporated into the kinase inhibitor discovery
pipeline to test these functions.
EXPERIMENTAL PROCEDURES
General Information
All assays were calibrated to ensure linearity of signal with respect to both sub-
strate and enzyme. Protein concentrations were determined by absorbance at
280 nm.
Statistical Analysis
Error bars represent SEM for three replicate measurements.
Small-Molecule Synthesis
Detailed procedures and commercial suppliers are provided in Supplemental
Experimental Procedures.
Cloning and Protein Expression
Detailed information is provided in Supplemental Experimental Procedures.
Activation Inhibition Assays: ELISA
These assays were performed based on the work of Sullivan et al. (2005).
Briefly, kinase was incubated in phosphorylation buffer (50 mM 3-[N-
morpholino]propanesulfonic acid [pH 7.4], 10 mM MgCl2, 1 mM dithiothreitol
[DTT], 0.001% [v/v] Tween 20) and BSA (0.1 mg/ml) with ATP (5 mM) and
titrated inhibitor (2% in DMSO) for 30 min at room temperature. Upstream ki-
nase (MEK2 for Erk2; MEK6 for p38) was then added, and the reactions were
incubated at room temperature. Downstream and upstream kinase concen-
trations as well as incubation times varied by kinase based on substrate line-
arity. The reactions were then quenched with 20 mM EDTA and bound
to polystyrene plates (Costar 96-well EIA/RIA 3590) overnight at 4C. Sub-
sequent ELISA was performed using primary antibodies specific for phos-
phorylated kinase (p38: Cell Signaling 4511; Erk2: Santa Cruz Biotechnology
16982) and a-rabbit horseradish peroxidase (HRP)-linked secondary anti-
body (Cell Signaling 7074). Activation inhibition values (EC50s) were deter-
mined by nonlinear regression using GraphPad Prism software.
Activation Inhibition Assays: Immunoblot
These assayswere performed essentially as describedabove, but ten times the
amount of MEK2 was added in the case of Erk2. The reactions were quenched
with SDS loading buffer without EDTA, and then separated by SDS-PAGE gels
cast with 50 mM PhosTag-acrylamide (Wako) and 100 mMMnCl2.Chemistry & Biology 21,In-Cell Activation Inhibition
Erk2WT or Erk2DS1 kinase genes in pcEGFP-LICwere transfected into low-pas-
sage HEK293 cells using FuGENE HD transfection reagent (Roche) and split
the next day into a 96-well plate. Cells were serum starved for 24 hr, after which
inhibitor was added (final 1%DMSO in culture media) and incubated for 1 hr at
37C. Human EGF (Cell Signaling; 50 ng/ml) was then added to each well and
incubated at 37C for 5 min. Cells were lysed by boiling in SDS loading buffer,
and cleared lysates were separated by SDS-PAGE. Transferred membranes
were immunoblotted with mouse a-GFP and rabbit a-ppErk (Cell Signaling
2955 and 4370, respectively) and imaged with a LI-COR Odyssey scanner.
Phosphatase Inhibition
Phosphorylated kinase (20 nM) was pretitrated with inhibitor for 30 min in buffer
(50mMHEPES [pH 7.4], 300mMNaCl, 5mMDTT, 0.1mg/ml BSA) before incu-
bationwithDUSP for1 hr. TheamountofDUSPaddedvariedbypreparation and
was tested for linearity before use. Reactionswere quenchedwith 8mMNa3VO4
andbound to polystyrene plates (Costar 96-well EIA/RIA 3590) overnight at 4C.
Subsequent ELISA was performed using primary antibodies specific for phos-
phorylated kinase (p38: Cell Signaling 4511; Erk2: Santa Cruz Biotechnology
16982) and a-rabbit HRP-linked secondary antibody (Cell Signaling 7074).
EC50sweredeterminedbynonlinear regressionusingGraphPadPrismsoftware.
DUSP6 Activation
Either no kinase, Erk2WT, Erk2DS1, or Erk2DS2 (250 nM) was incubated with
DUSP6 (140 nM) for 1 hr at room temperature, after which 4-MUP (250 mM)
was added. Samples were read (excitation/emission [Ex/Em]: 355/460 nm)
after 2 hr at room temperature. Samples without either DUSP6 or Erk2 were
used for background correction.
DUSP6 Activation Inhibition: Single Concentration
Either no kinase, Erk2WT, or Erk2DS2 (1 mM) was incubated with inhibitor (1% in
DMSO, 5 mM) in buffer (50 mM HEPES [pH 7.4], 300 mM NaCl, 5 mM DTT,
0.1 mg/ml BSA) for 30 min at room temperature. DUSP6 (140 nM) was added,
and the solutions were incubated for 1 hr at room temperature, after which
4-MUP (250 mM) was added. Samples were read (Ex/Em: 355/460 nm) after
2 hr at room temperature. Samples without Erk2 were used for background
correction.
DUSP6 Activation Inhibition: Titration
Erk2 (100 nM) was preincubated with titrated inhibitor (1% in DMSO) in buffer
(50 mMHEPES [pH 7.4], 300 mMNaCl, 5 mM DTT, 0.1 mg/ml BSA) for 30 min.
DUSP6 (140 nM) was then added and allowed to incubate for 1 hr at room
temperature, after which 4-MUP (250 mM)was added. The reaction proceeded
for 2 hr at room temperature and then read (Ex/Em: 355/460 nm). EC50s were
determined by nonlinear regression using GraphPad Prism software.
DUSP6 Kinetics: Erk2
Titrated amounts of Erk2DS1 (starting at 3 mM) were preincubated with inhibitor
(10 mM, >99.9% bound) for 30 min in buffer (50 mM HEPES [pH 7.4], 300 mM628–635, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 633
Figure 7. Conformation-Selective Inhibitors Affect MAPK Activation
of DUSP6
(A) Schematic of Erk2-mediated activation of DUSP6.
(B) Ligands 2, 3, or SB203580 were added to unphosphorylated Erk2WT
or Erk2DS2. DUSP6 was then added to the reaction, followed by 4-MUP.
The phosphatase reaction was measured by monitoring the fluorescence
increase. Background subtraction was performed using samples without
kinase. ***p < 0.001.
(C) Titration of Erk2-mediated DUSP6 activation. Kact[Erk2] values are
280 ± 20 nM and 500 ± 140 nM for apo Erk2DS1 and the 2-Erk2DS1 complex,
respectively.
Error bars represent SEM for three replicate measurements. See also
Figure S3.
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Modulating Protein Kinase Regulatory InteractionsNaCl, 5 mM DTT, 0.05 mg/ml BSA), and then incubated with DUSP6 (140 nM)
for 1 hr before addition of 4-MUP (250 mM). Samples were read (Ex/Em: 355/
460 nm) after 2 hr at room temperature. Michaelis constants were determined
by nonlinear regression using GraphPad Prism software.
DUSP6 Kinetics: 4-MUP
Erk2DS1 (2 mM) was preincubated with inhibitor (10 mM, >99.9% bound)
for 30 min in buffer (50 mM HEPES [pH 7.4], 300 mM NaCl, 5 mM
DTT, 0.05 mg/ml BSA), and then incubated with DUSP6 (140 nM) for 1 hr634 Chemistry & Biology 21, 628–635, May 22, 2014 ª2014 Elsevierbefore addition of titrated 4-MUP. Samples were read (Ex/Em: 355/
460 nm) after 2 hr at room temperature. Due to the excessive fluores-
cence of 4-MUP, separate wells for each concentration of 4-MUP without
Erk2 or DUSP6 were prepared for background correction. Michaelis con-
stants were determined by nonlinear regression using GraphPad Prism
software.
Crystallography
Detailed procedures are provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The atomic coordinates and structure factors for 3-bound Erk2DS2 have been
deposited in the Protein Data Bank under ID code 4N4S.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.02.016.
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